Rimegepant 75 mg Results in Reductions in Monthly Migraine Days: Secondary Analysis of a Multicenter, Open Label Long-term Safety Study of Rimegepant for the Acute Treatment of Migraine (1793)
McGinley J, L’Italien G, Thiry A, Croop R, Coric V, Lipton R. Rimegepant 75 mg Results in Reductions in Monthly Migraine Days: Secondary Analysis of a Multicenter, Open Label Long-term Safety Study of Rimegepant for the Acute Treatment of Migraine (1793). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1793.Peer-Reviewed Original ResearchOral Rimegepant 75 mg Is Well-tolerated When Used Concomitantly with Injectable Anti-CGRP Monoclonal Antibodies: Results From a Multicenter, Long-term, Open-label Safety Study (4553)
Berman G, Kudrow D, Halverson P, Lipton R, Lovegren M, Thiry A, Jensen C, Zhang Y, Stock E, Conway C, Croop R, Coric V. Oral Rimegepant 75 mg Is Well-tolerated When Used Concomitantly with Injectable Anti-CGRP Monoclonal Antibodies: Results From a Multicenter, Long-term, Open-label Safety Study (4553). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.4553.Peer-Reviewed Original Research